“…The IRI has been used in many trials related to social cognition (427) (e.g., 329, 427–429) and neurophysiological studies (430, 431), in combination with MRI data (432–437), and appears to be predictive of performance on other tasks of social cognition (438–440). Atypical scores may arise in association with schizotypy (441), schizophrenia (256, 442–448), epilepsy (449, 450), ASD (156), Huntington’s disease (183, 184), Tourette syndrome (183), Alzheimer’s disease and mild cognitive impairment (451), frontotemporal dementia (452–454), post-traumatic stress disorder (455, 456), attention deficit-hyperactivity disorder (393), anorexia nervosa (457), Parkinson’s disease (458, 459), depression (273), traumatic brain injury (460), aphasia (461), multiple sclerosis (462), complex regional pain (463), and substance misuse (464). No significant difference to controls have also been found in other samples of patients with substance misuse (25, 26, 465), schizophrenia (466), first-episode psychosis (467), and first-degree relatives of patients with schizophrenia (468, 469).…”